EasySep™ Mouse CD8a Positive Selection Kit II

Immunomagnetic positive selection kit

New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

EasySep™ Mouse CD8a Positive Selection Kit II

Immunomagnetic positive selection kit

From: 830 USD
Catalog #
(Select a product)
Immunomagnetic positive selection kit
Add to Wish List

Product Advantages


  • Fast and easy-to-use

  • Up to 98% purity

  • No columns required

  • Isolated cells are not fluorochrome labeled

What's Included

  • EasySep™ Mouse CD8a Positive Selection Kit II (Catalog #18953)
    • EasySep™ Mouse CD8a Positive Selection II Component A, 0.5 mL
    • EasySep™ Mouse CD8a Positive Selection II Component B, 0.5 mL
    • EasySep™ Mouse FcR Blocker, 0.2 mL
    • EasySep™ Dextran RapidSpheres™ 50100, 1 mL
    • RoboSep™ Empty Vial
  • RoboSep™ Mouse CD8a Positive Selection Kit II (Catalog #18953RF)
    • EasySep™ Mouse CD8a Positive Selection II Component A, 0.5 mL
    • EasySep™ Mouse CD8a Positive Selection II Component B, 0.5 mL
    • EasySep™ Mouse FcR Blocker, 0.2 mL
    • EasySep™ Dextran RapidSpheres™ 50100, 1 mL
    • RoboSep™ Empty Vial
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125) x 2
Products for Your Protocol

Overview

The EasySep™ Mouse CD8a Positive Selection Kit II is designed to isolate CD8a+ cells from single-cell suspensions of splenocytes or other tissues by positive selection. Desired cells are targeted with antibody complexes recognizing CD8a and dextran-coated magnetic particles. Labeled cells are separated using an EasySep™ magnet without the use of columns. Cells of interest remain in the tube while unwanted cells are poured off.

This product replaces the EasySep™ Mouse CD8a Positive Selection Kit (Catalog #18753) for even faster cell isolations and does not result in the labeling of isolated cells with PE.
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
T Cells, T Cells, CD8+
Species
Mouse
Sample Source
Other, Spleen
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Typical EasySep™ CD8a Positive Selection Profile

Figure 1. Typical EasySep™ CD8a Positive Selection Profile

Starting with mouse splenocytes, the CD8a+ cell content of the isolated fraction is typically 96.3 ± 1.4% (mean ± SD), using the purple EasySep™ magnet. In the above example, the purities of the start and final isolated fractions are 13.3% and 96.1%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
18953
Lot #
All
Language
English
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
18953
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
18953
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
18953
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
18953
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
18953RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
18953RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (2)

RIG-I-like receptor LGP2 is required for tumor control by radiation therapy. W. Zheng et al. Cancer research 2020 oct

Abstract

Dendritic cells (DC) play an essential role in innate immunity and radiation-elicited immune responses. LGP2 is a RIG-I like receptor (RLR) involved in cytoplasmic RNA recognition and anti-viral responses. Although LGP2 has also been linked to cell survival of both tumor cells and T cells, the role of LGP2 in mediating DC function and anti-tumor immunity elicited by radiotherapy remains unclear. Here we report that tumor DC are linked to the clinical outcome of breast cancer patients who received radiotherapy (RT) and the presence of DC correlates with gene expression of LGP2 in the tumor microenvironment. In preclinical models, host LGP2 was essential for optimal anti-tumor control by ionizing radiation (IR). The absence of LGP2 in DC dampened type I interferon production and the priming capacity of DC. In the absence of LGP2, MDA5-mediated activation of type I IFN signaling was abrogated. The MDA5/LGP2 agonist high molecular weight poly I: C improved the anti-tumor effect of IR. This study reveals a previously undefined role of LGP2 in host immunity and provides a new strategy to improve the efficacy of radiotherapy.
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. M. Compte et al. Nature communications 2018 NOV

Abstract

The costimulation of immune cells using first-generation anti-4-1BB monoclonal antibodies (mAbs) has demonstrated anti-tumor activity in human trials. Further clinical development, however, is restricted by significant off-tumor toxicities associated with Fc$\gamma$R interactions. Here, we have designed an Fc-free tumor-targeted 4-1BB-agonistic trimerbody, 1D8N/CEGa1, consisting of three anti-4-1BB single-chain variable fragments and three anti-EGFR single-domain antibodies positioned in an extended hexagonal conformation around the collagen XVIII homotrimerization domain. The1D8N/CEGa1 trimerbody demonstrated high-avidity binding to 4-1BB and EGFR and a potent in vitro costimulatory capacity in the presence of EGFR. The trimerbody rapidly accumulates in EGFR-positive tumors and exhibits anti-tumor activity similar to IgG-based 4-1BB-agonistic mAbs. Importantly, treatment with 1D8N/CEGa1 does not induce systemic inflammatory cytokine production or hepatotoxicity associated with IgG-based 4-1BB agonists. These results implicate Fc$\gamma$R interactions in the 4-1BB-agonist-associated immune abnormalities, and promote the use of the non-canonical antibody presented in this work for safe and effective costimulatory strategies in cancer immunotherapy.
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more